Press Releases

Date	Title
March 15, 2021	Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess
March 1, 2021	Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer
February 23, 2021	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
February 8, 2021	Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update
February 1, 2021	Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call